Home » Newsletters » BioWorld Science

BioWorld Science

March 27, 1997

View Archived Issues

Company Profile: MetaMorphix

Company Profile: T Cell Sciences

Rhone-Poulenc Rorer's Granocyte approved for additional indication

Millenium issued U.S. patents related to drug discovery

Alpha-adrenoceptor blockers from SKB

Allelix prepares PTH variants for osteoporosis

Evanston Hospital discloses radio- and chemosensitizers

NKA antagonists claimed by Zeneca

New anxiolytics from American Home Products

Diagnostic use of radiolabeled lisinopril derivatives disclosed by Merck Frosst

Bristol-Myers Squibb discovers new ribosome-inactivating protein

Sanofi discloses agents for treating CRF-related disorders

Hybridon announces year-end financial results for 1996

BioChem Pharma announces fourth-quarter and 1996 results

Noven discusses year-end results and 1997 outlook

OXiGENE reports 1996 financial results

Triangle Pharmaceuticals reports financial results

Xoma reports financial results for 1996

CoCensys reports 1996 fourth-quarter and year-end financial results

Therapeutic Antibodies announces results for the year ended December 31, 1996

U.S. timetable for Gadolite adjusted

Pharmacia & Upjohn seeks FDA approval for incontinence drug

CAT and Techniclone to initiate trials for tumor therapy

Novel orally active antithrombotic agent from Fuji Yakuhin

Armenian researchers describe novel antiarrhythmic agent

Theratechnologies reports development strategy for second GRF analogue

Antiplatelet 5-HT2A receptor antagonist characterized by Toa Eiyo

Update on NABI's HIV-IG clinical trials

Kaken prepares broad-spectrum antiulcer agent

Cheung Laboratories initiates preclinicals of BPH treatment system

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MicroRNAs in circulating extracellular vesicles as IPF biomarkers
BioWorld Science
MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...